← Back to Search

Artificial Inteligence in Endoscopic Ultrasound

N/A
Recruiting
Led By Shyam Varadarajulu, MD
Research Sponsored by Orlando Health, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day
Awards & highlights
No Placebo-Only Group

Summary

The objective of the study is to determine if this artificial intelligence system is capable of detecting abnormalities in the pancreas that are identified by an endoscopist at endoscopic ultrasound procedures.

Eligible Conditions
  • Pancreatic Cysts
  • Pancreatic Cyst
  • Pancreatic Disease
  • Pancreatic Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Rate of detection pancreatic abnormalities by AI
Secondary study objectives
Rate of detection pancreatic cystic lesions by AI
Rate of detection pancreatic solid mass lesions by AI

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patients undergoing endoscopic ultrasound proceduresExperimental Treatment1 Intervention
Patients will undergo endoscopic ultrasound procedures as planned. Abnormalities in the pancreas identified by the endoscopist during the endoscopic ultrasound examination will be correlated against those detected by the AI platform.

Find a Location

Who is running the clinical trial?

Orlando Health, Inc.Lead Sponsor
31 Previous Clinical Trials
13,617 Total Patients Enrolled
Shyam Varadarajulu, MDPrincipal InvestigatorOrlando Health, Digestive Health Institute
26 Previous Clinical Trials
5,902 Total Patients Enrolled
~1000 spots leftby Dec 2026